Modi-1 cancer vaccine for several hard-to-treat cancers
Treatments studied
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these advanced cancers: triple-negative breast, head and neck (SCCHN), high-grade serous ovarian/peritoneal, or renal cell cancer (kidney cancer).
- Your cancer must be advanced and usually not curable with surgery, OR you may be in a head-and-neck surgery timing group.
- You must have measurable tumor spots on a CT or MRI scan (not just symptoms).
- You must be well enough to do study tasks (age 18+ and general health rating ECOG 0 or 1).
- You need certain blood test and organ health levels (for example, bone marrow, kidneys, and liver).
- If you will receive an immune drug (like pembrolizumab, nivolumab, and possibly ipilimumab), you likely must not have had that type of drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a personalized cancer vaccine for triple negative breast cancer. It is given alongside standard chemotherapy and immunotherapy to help your immune system fight the cancer.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.